Price Alert

Protagonist Therapeutics ... (PTGX)

NASDAQ: PTGX · Real-Time Price · USD

56.04

1.05 (1.91%)

At close: Aug 15, 2025, 3:59 PM

56.07

0.05%

After-hours: Aug 15, 2025, 04:34 PM EDT

Protagonist Therapeutics Statistics

Share Statistics

Protagonist Therapeutics has 62.21M shares outstanding. The number of shares has increased by 5.22% in one year.

Shares Outstanding	62.21M
Shares Change (YoY)	5.22%
Shares Change (QoQ)	0.97%
Owned by Institutions (%)	99.99%
Shares Floating	58.61M
Failed to Deliver (FTD) Shares	170
FTD / Avg. Volume	0.02%

Short Selling Information

The latest short interest is 6.18M, so 9.98% of the outstanding shares have been sold short.

Short Interest	6.18M
Short % of Shares Out	9.98%
Short % of Float	11.97%
Short Ratio (days to cover)	7.88

Valuation Ratios

The PE ratio is 8.64 and the forward PE ratio is -283.67. Protagonist Therapeutics's PEG ratio is -0.02.

PE Ratio	8.64
Forward PE	-283.67
PS Ratio	5.47
Forward PS	16.6
PB Ratio	3.52
P/FCF Ratio	13
PEG Ratio	-0.02

Financial Ratio History

Enterprise Valuation

Protagonist Therapeutics has an Enterprise Value (EV) of 2.29B.

EV / Sales	5.27
EV / EBITDA	9.06
EV / EBIT	12.44
EV / FCF	12.53

Financial Position

The company has a current ratio of 12.48, with a Debt / Equity ratio of 0.02.

Current Ratio	12.48
Quick Ratio	12.48
Debt / Equity	0.02
Debt / EBITDA	0.04
Debt / FCF	0.06
Interest Coverage	0

Financial Efficiency

Return on Equity is 40.75% and Return on Invested Capital is 35.69%.

Return on Equity	40.75%
Return on Assets	36.95%
Return on Invested Capital	35.69%
Revenue Per Employee	$3.5M
Profits Per Employee	$2.22M
Employee Count	124
Asset Turnover	0.58
Inventory Turnover	n/a

Taxes

Income Tax	4.22M
Effective Tax Rate	1.51%

Stock Price Statistics

The stock price has increased by 32.44% in the last 52 weeks. The beta is 2.33, so Protagonist Therapeutics's price volatility has been higher than the market average.

Beta	2.33
52-Week Price Change	32.44%
50-Day Moving Average	53.6
200-Day Moving Average	45.73
Relative Strength Index (RSI)	37.6
Average Volume (20 Days)	816,190

Income Statement

In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.

Revenue	434.43M
Gross Profit	431.47M
Operating Income	252.84M
Net Income	275.19M
EBITDA	252.84M
EBIT	252.84M
Earnings Per Share (EPS)	4.47

Full Income Statement

Balance Sheet

The company has 97.25M in cash and 10.87M in debt, giving a net cash position of 86.38M.

Cash & Cash Equivalents	97.25M
Total Debt	10.87M
Net Cash	86.38M
Retained Earnings	-340.52M
Total Assets	718.01M
Working Capital	567.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 184.15M and capital expenditures -1.35M, giving a free cash flow of 182.8M.

Operating Cash Flow	184.15M
Capital Expenditures	-1.35M
Free Cash Flow	182.8M
FCF Per Share	2.97

Full Cash Flow Statement

Margins

Gross margin is 99.32%, with operating and profit margins of 58.2% and 63.34%.

Gross Margin	99.32%
Operating Margin	58.2%
Pretax Margin	64.32%
Profit Margin	63.34%
EBITDA Margin	58.2%
EBIT Margin	58.2%
FCF Margin	42.08%

Dividends & Yields

PTGX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	11.58%
FCF Yield	7.69%

Dividend Details

Analyst Forecast

The average price target for PTGX is $70, which is 30.2% higher than the current price. The consensus rating is "Buy".

Price Target	$70
Price Target Difference	30.2%
Analyst Consensus	Buy
Analyst Count	9

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	33.21
Graham Upside	-38.24%

Scores

Altman Z-Score	38.72
Piotroski F-Score	4